Company intelligence / Profile preview
Rznomics
Yongin-si, Gyeonggi-do, South Korearznomics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Rznomics’ lead candidate RZ-001 uses a replication-incompetent adenoviral vector encoding a trans-splicing ribozyme targeting hTERT mRNA. It has reached Phase 1/2a clinical trials for hepatocellular carcinoma and glioblastoma. The company has received Orphan Drug Designation for hepatocellular carcinoma and Fast Track Designation for glioblastoma from the US FDA. Other programs are in IND or preclinical stages targeting genetic eye disorders and neurodegeneration
- Therapeutic areas
- OphthalmologyOncologyNeurology
- Modalities
- RNA-based gene therapytrans-splicing ribozyme technologyAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Rznomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rznomics.